{
    "Case ID": "004754",
    "Different Crime": [
        {
            "Crime Name": "Patent Infringement Dispute",
            "Crime Type": "Economic_Crimes_or_Fraud-related_Offenses",
            "applicable_statute": [
                "Patented Medicines (Notice of Compliance) Regulations, SOR/93-133"
            ],
            "expert_testimony": [
                "Experts agreed HPMC and HPC are similar but differ on whether HPMC is essential"
            ],
            "patent_validity": [
                "Court found HPMC essential to '320 patent claims, excluding HPC as a variant. For '754, the disclosure focused on osmotic systems, not hydrogel processes like Novopharmâ€™s."
            ],
            "decision_outcome": [
                "Biovail's application dismissed; Novopharm does not infringe either patent"
            ],
            "cause_of_action": [
                "Biovail sought to prevent Novopharm from obtaining regulatory approval for a generic version of Wellbutrin(r) SR, alleging patent infringement"
            ],
            "technical_details": [
                "Whether Novopharm's proposed drug infringes Biovail's patents ('320 and '754) for Wellbutrin(r) SR."
            ],
            "appeal_outcome": [
                "Novopharm can proceed with its drug development without waiting for patent expiration. Biovail's attempt to block was unsuccessful."
            ]
        }
    ]
}